TY  - JOUR
AU  - Brown, J William L
AU  - Coles, Alasdair
AU  - Horakova, Dana
AU  - Havrdova, Eva
AU  - Izquierdo, Guillermo
AU  - Prat, Alexandre
AU  - Girard, Marc
AU  - Duquette, Pierre
AU  - Trojano, Maria
AU  - Lugaresi, Alessandra
AU  - Bergamaschi, Roberto
AU  - Grammond, Pierre
AU  - Alroughani, Raed
AU  - Hupperts, Raymond
AU  - McCombe, Pamela
AU  - Van Pesch, Vincent
AU  - Sola, Patrizia
AU  - Ferraro, Diana
AU  - Grand'Maison, Francois
AU  - Terzi, Murat
AU  - Lechner-Scott, Jeannette
AU  - Flechter, Schlomo
AU  - Slee, Mark
AU  - Shaygannejad, Vahid
AU  - Pucci, Eugenio
AU  - Granella, Franco
AU  - Jokubaitis, Vilija
AU  - Willis, Mark
AU  - Rice, Claire
AU  - Scolding, Neil
AU  - Wilkins, Alastair
AU  - Pearson, Owen R
AU  - Ziemssen, Tjalf
AU  - Hutchinson, Michael
AU  - Harding, Katharine
AU  - Jones, Joanne
AU  - McGuigan, Christopher
AU  - Butzkueven, Helmut
AU  - Kalincik, Tomas
AU  - Robertson, Neil
AU  - MSBase Study Group
PY  - 2019
DO  - 10.1001/jama.2018.20588
UR  - http://hdl.handle.net/10668/13424
T2  - JAMA
AB  - Within 2 decades of onset, 80% of untreated patients with relapsing-remitting multiple sclerosis (MS) convert to a phase of irreversible disability accrual termed secondary progressive MS. The association between disease-modifying treatments (DMTs),...
LA  - en
KW  - Adult
KW  - Alemtuzumab
KW  - Cohort Studies
KW  - Disease Progression
KW  - Female
KW  - Fingolimod Hydrochloride
KW  - Glatiramer Acetate
KW  - Humans
KW  - Immunologic Factors
KW  - Immunosuppressive Agents
KW  - Interferon-beta
KW  - Male
KW  - Multiple Sclerosis, Relapsing-Remitting
KW  - Natalizumab
KW  - Time-to-Treatment
TI  - Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis.
TY  - research article
VL  - 321
ER  -